VOORHEES, N.J., Aug. 4 /PRNewswire/ -- Treatment of glioblastoma (GBM), the most common type of glioma, presents many challenges. More than 50% of patients die of disease progression within 18 months of diagnosis. Current treatment includes the use of temozolomide-based chemotherapy, both concurrently with and after completion of radiotherapy. As healthcare professionals gain a better understanding of the molecular biology of GBM and utilize targeted therapies more frequently, there is hope for improving patient outcomes.
To address the need for current education on GBM, Robert Michael Educational Institute LLC (RMEI) and Postgraduate Institute for Medicine (PIM) are jointly sponsoring a complimentary continuing education monograph titled Adult Glioblastoma: Optimal Approaches to a Challenging Diagnosis. This activity, which is accredited for physicians, pharmacists and registered nurses, is supported by an educational grant from Schering-Plough Corporation.
Marc C. Chamberlain, MD, from the University of Washington and the Fred Hutchinson Cancer Research Center in Seattle, Washington, serves as faculty reviewer for the monograph.
Healthcare professionals can visit www.RMEI.com/GBMonograph to participate in this complimentary continuing education activity.
"Quality continuing medical education is vital to developing and increasing knowledge and skills and enhancing patient care," says Robert Michael Educational Institute LLC President and CEO, Robert M. Colleluori.
RMEI is a medical education company that specializes in independent, certified, and non-certified education. The goal of all certified RMEI educational offerings is to promote a spirit of lifelong learning and continuous professional development. RMEI works closely with medical experts to design activities that
|SOURCE Robert Michael Educational Institute LLC|
Copyright©2009 PR Newswire.
All rights reserved